JP2012107050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012107050A5 JP2012107050A5 JP2012037811A JP2012037811A JP2012107050A5 JP 2012107050 A5 JP2012107050 A5 JP 2012107050A5 JP 2012037811 A JP2012037811 A JP 2012037811A JP 2012037811 A JP2012037811 A JP 2012037811A JP 2012107050 A5 JP2012107050 A5 JP 2012107050A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- hvr
- amino acid
- host cell
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (12)
- 配列番号38、配列番号39、配列番号45および配列番号41に示されるアミノ酸配列を含む可変領域重鎖フレームワーク配列、ならびに配列番号15に示されるアミノ酸配列のアミノ酸残基1〜23、24〜37、38〜69および70〜最後の残基を含む可変領域軽鎖フレームワーク配列、ならびにRASESVDDLLH(配列番号9)を含むHVR−L1、KYASQSIS(配列番号2)を含むHVR−L2、QQGNSLPNT(配列番号3)を含むHVR−L3、GFFITNNYWG(配列番号4)を含むHVR−H1、GYISYSGSTSYNPSLKS(配列番号5)を含むHVR−H2およびMTGSSGYFDF(配列番号6)を含むHVR−H3を含むヒト化抗ベータ7抗体をコードするポリヌクレオチド。
- 配列番号38、配列番号39、配列番号45および配列番号41に示されるアミノ酸配列を含む可変領域重鎖フレームワーク配列、ならびに配列番号15に示されるアミノ酸配列のアミノ酸残基1〜23、24〜37、38〜69および70〜最後の残基を含む可変領域軽鎖フレームワーク配列、ならびにRASESVDDLLH(配列番号9)を含むHVR−L1、KYASQSIS(配列番号2)を含むHVR−L2、QQGNSLPNT(配列番号3)を含むHVR−L3、GFFITNNYWG(配列番号4)を含むHVR−H1、GYISYSGSTSYNPSLKS(配列番号5)を含むHVR−H2およびRTGSSGYFDF(配列番号66)を含むHVR−H3を含むヒト化抗ベータ7抗体をコードするポリヌクレオチド。
- 配列番号38、配列番号39、配列番号45および配列番号41に示されるアミノ酸配列を含む可変領域重鎖フレームワーク配列、ならびに配列番号15に示されるアミノ酸配列のアミノ酸残基1〜23、24〜37、38〜69および70〜最後の残基を含む可変領域軽鎖フレームワーク配列、ならびにRASESVDSLLH(配列番号7)を含むHVR−L1、KYASQSIS(配列番号2)を含むHVR−L2、QQGNSLPNT(配列番号3)を含むHVR−L3、GFFITNNYWG(配列番号4)を含むHVR−H1、GYISYSGSTSYNPSLKS(配列番号5)を含むHVR−H2およびMTGSSGYFDF(配列番号6)を含むHVR−H3を含むヒト化抗ベータ7抗体をコードするポリヌクレオチド。
- 請求項1〜3のいずれか一項に記載のポリヌクレオチドを含むベクター。
- 請求項4に記載のベクターを含む宿主細胞。
- 原核生物の細胞である、請求項5に記載の宿主細胞。
- E.coliである、請求項6に記載の宿主細胞。
- 真核生物の細胞である、請求項5に記載の宿主細胞。
- 哺乳類細胞である、請求項8に記載の宿主細胞。
- チャイニーズハムスター卵巣細胞である、請求項9に記載の宿主細胞。
- ヒト化抗ベータ7抗体を生成する方法であって、該方法は、請求項5〜10のいずれか一項に記載の宿主細胞を培養する工程を包含する、方法。
- 前記宿主細胞によって発現された前記抗体を精製する工程をさらに包含する、請求項11に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60737704P | 2004-09-03 | 2004-09-03 | |
US60/607,377 | 2004-09-03 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007530413A Division JP5062887B2 (ja) | 2004-09-03 | 2005-09-02 | ヒト化抗β7アンタゴニストおよびその使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012107050A JP2012107050A (ja) | 2012-06-07 |
JP2012107050A5 true JP2012107050A5 (ja) | 2013-04-18 |
JP5255135B2 JP5255135B2 (ja) | 2013-08-07 |
Family
ID=36000753
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007530413A Expired - Fee Related JP5062887B2 (ja) | 2004-09-03 | 2005-09-02 | ヒト化抗β7アンタゴニストおよびその使用 |
JP2012037811A Active JP5255135B2 (ja) | 2004-09-03 | 2012-02-23 | ヒト化抗β7アンタゴニストおよびその使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007530413A Expired - Fee Related JP5062887B2 (ja) | 2004-09-03 | 2005-09-02 | ヒト化抗β7アンタゴニストおよびその使用 |
Country Status (27)
Country | Link |
---|---|
US (10) | US7528236B2 (ja) |
EP (4) | EP1784426B1 (ja) |
JP (2) | JP5062887B2 (ja) |
KR (2) | KR101364276B1 (ja) |
CN (3) | CN103304667B (ja) |
AT (1) | ATE534668T1 (ja) |
AU (1) | AU2005279720B2 (ja) |
BR (1) | BRPI0515602B1 (ja) |
CA (1) | CA2577678C (ja) |
CY (2) | CY1112277T1 (ja) |
DK (4) | DK3530673T3 (ja) |
ES (4) | ES2377979T3 (ja) |
HK (5) | HK1112002A1 (ja) |
HR (3) | HRP20120171T1 (ja) |
HU (3) | HUE058817T2 (ja) |
IL (3) | IL181473A (ja) |
LT (2) | LT3530673T (ja) |
MX (3) | MX337423B (ja) |
NO (3) | NO341308B1 (ja) |
NZ (2) | NZ585628A (ja) |
PL (4) | PL3530673T3 (ja) |
PT (3) | PT1784426E (ja) |
RS (3) | RS57636B1 (ja) |
RU (1) | RU2453558C2 (ja) |
SI (4) | SI2322556T1 (ja) |
WO (1) | WO2006026759A2 (ja) |
ZA (1) | ZA200701575B (ja) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100591336C (zh) * | 2002-11-08 | 2010-02-24 | 汪建平 | 菱角提取物及其使用方法 |
CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
HUE058817T2 (hu) * | 2004-09-03 | 2022-09-28 | Genentech Inc | Humanizált anti-béta7 antagonisták és alkalmazásaik |
EP2808033A1 (en) * | 2004-11-19 | 2014-12-03 | Biogen Idec MA Inc. | Treatment for multiple sclerosis |
US10982250B2 (en) * | 2006-09-18 | 2021-04-20 | Genentech, Inc. | Methods of protein production |
US9193790B2 (en) | 2006-12-07 | 2015-11-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of antagonists of the interaction between HIV GP120 and A4B7 integrin |
CA2676790A1 (en) | 2007-02-22 | 2008-08-28 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
PE20090245A1 (es) * | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
JP5440179B2 (ja) | 2008-01-11 | 2014-03-12 | アステラス製薬株式会社 | 改良型ヒト化抗ヒトα9インテグリン抗体 |
US9029508B2 (en) * | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
EP2279004B1 (en) * | 2008-05-16 | 2015-01-14 | F. Hoffmann-La Roche AG | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists |
PE20100054A1 (es) * | 2008-06-03 | 2010-03-03 | Abbott Lab | Inmunoglobulina con dominio variable dual |
PE20100092A1 (es) * | 2008-06-03 | 2010-03-12 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
RU2011104348A (ru) * | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
SG175166A1 (en) * | 2009-04-17 | 2011-11-28 | Biogen Idec Inc | Compositions and methods to treat acute myelogenous leukemia |
US8399625B1 (en) * | 2009-06-25 | 2013-03-19 | ESBATech, an Alcon Biomedical Research Unit, LLC | Acceptor framework for CDR grafting |
TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
NZ598929A (en) * | 2009-09-01 | 2014-05-30 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
AR078651A1 (es) * | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
EP2494354A1 (en) * | 2009-10-30 | 2012-09-05 | Merck Sharp & Dohme Corp. | Pcsk9 immunoassay |
CA2787952C (en) * | 2010-02-23 | 2016-07-26 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of ovarian cancer |
JP2013523843A (ja) * | 2010-04-15 | 2013-06-17 | ベジェニクス ピーティーワイ リミテッド | Vegf−c拮抗剤を用いた併用治療 |
LT2558499T (lt) | 2010-04-16 | 2017-07-25 | Biogen Ma Inc. | Antikūnai prieš vla-4 |
MY160445A (en) | 2010-08-03 | 2017-03-15 | Abbvie Inc | Dual Variable Domain Immunoglobulins And Uses Thereof |
JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
JP2014500712A (ja) * | 2010-11-02 | 2014-01-16 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
MY189494A (en) * | 2011-03-31 | 2022-02-16 | Genentech Inc | Methods of administering beta7 integrin antagonists |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
KR102014512B1 (ko) | 2011-05-02 | 2019-08-26 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
EP2797955A2 (en) | 2011-12-30 | 2014-11-05 | AbbVie Inc. | Dual variable domain immunoglobulins against il-13 and/or il-17 |
US20150010563A1 (en) * | 2012-02-21 | 2015-01-08 | Massachusetts Eye & Ear Infirmary | Methods for Treating Corneal and Conjunctival Inflammation and Inflammatory Disorders |
RS58964B1 (sr) | 2012-03-13 | 2019-08-30 | Hoffmann La Roche | Kombinovana terapija za lečenje karcinoma jajnika |
US10078085B2 (en) | 2012-08-22 | 2018-09-18 | Mogam Biothechnology Institute | Screening and engineering method of super-stable immunoglobulin variable domains and their uses |
RU2015112024A (ru) | 2012-10-05 | 2016-11-27 | Дженентек, Инк. | Способы диагностики и лечения воспалительного заболевания кишечника |
KR20210111353A (ko) | 2012-11-01 | 2021-09-10 | 애브비 인코포레이티드 | 항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도 |
EP2970459A2 (en) | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Dual specific binding proteins directed against il-1beta and il-17 |
WO2014160753A1 (en) | 2013-03-27 | 2014-10-02 | Genentech, Inc. | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
RU2016136716A (ru) | 2014-03-27 | 2018-04-28 | Дженентек, Инк. | Способы диагностики и лечения воспалительного заболевания кишечника |
US20170327584A1 (en) | 2014-11-26 | 2017-11-16 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the Treatment of Fistulizing Crohn's Disease |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
JP2018507868A (ja) | 2015-02-26 | 2018-03-22 | ジェネンテック, インコーポレイテッド | インテグリンベータ7アンタゴニスト及びクローン病の治療方法 |
MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
CN108139385A (zh) * | 2015-07-27 | 2018-06-08 | 豪夫迈·罗氏有限公司 | 用于诊断和治疗炎症性肠病的方法 |
CN117298268A (zh) | 2016-03-14 | 2023-12-29 | 千禧制药公司 | 治疗或预防移植物抗宿主疾病的方法 |
MX2018011169A (es) | 2016-03-14 | 2018-12-06 | Millennium Pharm Inc | Metodo para prevenir la enfermedad del injerto contra huesped. |
EP3433275A1 (en) | 2016-03-24 | 2019-01-30 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
KR20220119529A (ko) | 2016-06-02 | 2022-08-29 | 애브비 인코포레이티드 | 글루코코르티코이드 수용체 작용제 및 이의 면역접합체 |
CN109414502A (zh) | 2016-06-12 | 2019-03-01 | 千禧制药公司 | 治疗炎症性肠病的方法 |
MX2019012749A (es) | 2017-04-28 | 2020-02-03 | Millennium Pharm Inc | Metodos para tratar trastornos pediatricos. |
ES2877659T3 (es) | 2017-12-01 | 2021-11-17 | Abbvie Inc | Agonista del receptor de glucocorticoides y sus inmunoconjugados |
AR114489A1 (es) | 2018-04-12 | 2020-09-09 | Morphic Therapeutic Inc | ANTAGONISTAS DE LA INTEGRINA a4b7 HUMANA |
US20220372132A1 (en) * | 2019-01-10 | 2022-11-24 | Sg Medical Inc. | Anti-beta 1 integrin humanized antibody, and pharmaceutical composition for treating cancer, comprising same |
WO2020252072A1 (en) * | 2019-06-10 | 2020-12-17 | Millennium Pharmaceuticals, Inc. | Antibody purification methods and compositions thereof |
EP4045039A4 (en) | 2019-10-16 | 2023-12-13 | Morphic Therapeutic, Inc. | INHIBITION OF HUMAN INTEGRIN ALPHA4BETA7 |
CA3190109A1 (en) | 2020-07-31 | 2022-02-03 | Genentech, Inc. | Anti-integrin beta7 antibody formulations and devices |
WO2023086910A1 (en) | 2021-11-12 | 2023-05-19 | Genentech, Inc. | Methods of treating crohn's disease using integrin beta7 antagonists |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) * | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) * | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4265814A (en) * | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) * | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) * | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) * | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) * | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) * | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
US4308428A (en) * | 1979-12-26 | 1981-12-29 | Cbs Inc. | System for electronically simulating radiation effects produced by a rotary loudspeaker |
US4331348A (en) * | 1980-01-09 | 1982-05-25 | Raidel John E | Vehicle suspension |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) * | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5079233A (en) * | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
WO1988007089A1 (en) * | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5770701A (en) * | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5053394A (en) * | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5606040A (en) * | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) * | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
CA2405246A1 (en) * | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
ATE199392T1 (de) * | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US5610281A (en) * | 1994-05-03 | 1997-03-11 | Brigham & Women's Hospital, Inc. | Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes |
US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
AU4986296A (en) * | 1995-02-10 | 1996-08-27 | Leukosite Incorporated | Mucosal vascular addressins and uses thereof |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
AU2660397A (en) | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
JP2002530355A (ja) | 1998-11-25 | 2002-09-17 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ レプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 炎症性疾患のための治療剤としてのαEβ7インテグリンのアンタゴニスト |
WO2000040604A2 (en) * | 1999-01-08 | 2000-07-13 | The Brigham And Women's Hospital, Inc. | METHODS AND COMPOSITIONS FOR MODULATING CYTOKINE RELEASE BY αEβ7-EXPRESSING CELLS |
US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
ATE339169T1 (de) * | 2002-02-06 | 2006-10-15 | Koninkl Philips Electronics Nv | System für die persönliche pflege mit hygienevorrichtung und kühlvorrichtung |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
AP2006003689A0 (en) | 2004-01-09 | 2006-08-31 | Pfizer | Antibodies to MAdCAM |
EP2168986A3 (en) | 2004-02-19 | 2010-07-28 | Genentech, Inc. | CDR-repaired antibodies |
HUE058817T2 (hu) | 2004-09-03 | 2022-09-28 | Genentech Inc | Humanizált anti-béta7 antagonisták és alkalmazásaik |
US10982250B2 (en) | 2006-09-18 | 2021-04-20 | Genentech, Inc. | Methods of protein production |
JP2007302676A (ja) | 2007-05-29 | 2007-11-22 | Genentech Inc | ヒト化抗β7アンタゴニストおよびその使用 |
-
2005
- 2005-09-02 HU HUE18181899A patent/HUE058817T2/hu unknown
- 2005-09-02 PT PT05810856T patent/PT1784426E/pt unknown
- 2005-09-02 WO PCT/US2005/031401 patent/WO2006026759A2/en active Application Filing
- 2005-09-02 DK DK18181899.8T patent/DK3530673T3/da active
- 2005-09-02 ES ES05810856T patent/ES2377979T3/es active Active
- 2005-09-02 HU HUE15185749A patent/HUE039591T2/hu unknown
- 2005-09-02 SI SI200532031T patent/SI2322556T1/sl unknown
- 2005-09-02 RS RS20181006A patent/RS57636B1/sr unknown
- 2005-09-02 SI SI200531466T patent/SI1784426T1/sl unknown
- 2005-09-02 PL PL18181899.8T patent/PL3530673T3/pl unknown
- 2005-09-02 DK DK05810856.4T patent/DK1784426T3/da active
- 2005-09-02 MX MX2015008311A patent/MX337423B/es unknown
- 2005-09-02 LT LTEP18181899.8T patent/LT3530673T/lt unknown
- 2005-09-02 CN CN201310216951.8A patent/CN103304667B/zh active Active
- 2005-09-02 KR KR1020077007524A patent/KR101364276B1/ko active IP Right Grant
- 2005-09-02 EP EP05810856A patent/EP1784426B1/en active Active
- 2005-09-02 ZA ZA200701575A patent/ZA200701575B/xx unknown
- 2005-09-02 AU AU2005279720A patent/AU2005279720B2/en active Active
- 2005-09-02 CN CN2005800381869A patent/CN101094868B/zh active Active
- 2005-09-02 SI SI200532226T patent/SI2990422T1/sl unknown
- 2005-09-02 US US11/219,121 patent/US7528236B2/en active Active
- 2005-09-02 KR KR1020127024637A patent/KR101433494B1/ko active IP Right Grant
- 2005-09-02 LT LTEP15185749.7T patent/LT2990422T/lt unknown
- 2005-09-02 CA CA2577678A patent/CA2577678C/en active Active
- 2005-09-02 BR BRPI0515602-5A patent/BRPI0515602B1/pt not_active IP Right Cessation
- 2005-09-02 PL PL05810856T patent/PL1784426T3/pl unknown
- 2005-09-02 PT PT101774073T patent/PT2322556E/pt unknown
- 2005-09-02 JP JP2007530413A patent/JP5062887B2/ja not_active Expired - Fee Related
- 2005-09-02 PL PL15185749T patent/PL2990422T3/pl unknown
- 2005-09-02 NZ NZ585628A patent/NZ585628A/en not_active IP Right Cessation
- 2005-09-02 RS RS20120055A patent/RS52213B/en unknown
- 2005-09-02 EP EP15185749.7A patent/EP2990422B1/en active Active
- 2005-09-02 MX MX2007002675A patent/MX2007002675A/es active IP Right Grant
- 2005-09-02 SI SI200532306T patent/SI3530673T1/sl unknown
- 2005-09-02 DK DK10177407.3T patent/DK2322556T3/en active
- 2005-09-02 ES ES10177407.3T patent/ES2555355T3/es active Active
- 2005-09-02 NZ NZ553328A patent/NZ553328A/en not_active IP Right Cessation
- 2005-09-02 MX MX2016002850A patent/MX341370B/es unknown
- 2005-09-02 ES ES18181899T patent/ES2911482T3/es active Active
- 2005-09-02 ES ES15185749.7T patent/ES2690079T3/es active Active
- 2005-09-02 EP EP18181899.8A patent/EP3530673B1/en active Active
- 2005-09-02 EP EP10177407.3A patent/EP2322556B1/en active Active
- 2005-09-02 PL PL10177407T patent/PL2322556T3/pl unknown
- 2005-09-02 CN CN201510105194.6A patent/CN104710532B/zh active Active
- 2005-09-02 AT AT05810856T patent/ATE534668T1/de active
- 2005-09-02 DK DK15185749.7T patent/DK2990422T3/en active
- 2005-09-02 PT PT15185749T patent/PT2990422T/pt unknown
- 2005-09-02 RS RS20150775A patent/RS54409B1/en unknown
- 2005-09-02 RU RU2007112102/10A patent/RU2453558C2/ru active
- 2005-09-02 HU HUE10177407A patent/HUE028441T2/hu unknown
-
2007
- 2007-02-21 IL IL181473A patent/IL181473A/en active IP Right Grant
- 2007-03-02 US US11/681,512 patent/US7687605B2/en active Active
- 2007-04-02 NO NO20071740A patent/NO341308B1/no unknown
-
2008
- 2008-06-13 HK HK08106559.2A patent/HK1112002A1/xx not_active IP Right Cessation
- 2008-06-13 HK HK14102016.0A patent/HK1188798A1/xx not_active IP Right Cessation
-
2009
- 2009-02-23 US US12/390,730 patent/US8124082B2/en not_active Expired - Fee Related
-
2011
- 2011-10-18 HK HK11111098.5A patent/HK1156955A1/zh not_active IP Right Cessation
-
2012
- 2012-01-12 US US13/348,709 patent/US8779100B2/en active Active
- 2012-01-30 CY CY20121100102T patent/CY1112277T1/el unknown
- 2012-02-21 HR HR20120171T patent/HRP20120171T1/hr unknown
- 2012-02-23 JP JP2012037811A patent/JP5255135B2/ja active Active
-
2013
- 2013-03-07 US US13/788,246 patent/US8835133B2/en active Active
- 2013-06-04 IL IL226717A patent/IL226717A/en active IP Right Grant
-
2014
- 2014-08-08 US US14/454,884 patent/US20150197560A1/en not_active Abandoned
-
2015
- 2015-11-30 HK HK15111758.2A patent/HK1210977A1/xx not_active IP Right Cessation
-
2016
- 2016-01-13 HR HRP20160034TT patent/HRP20160034T1/hr unknown
- 2016-01-15 CY CY20161100039T patent/CY1117124T1/el unknown
- 2016-03-24 US US15/079,804 patent/US20170044261A1/en not_active Abandoned
- 2016-03-28 IL IL244803A patent/IL244803B/en active IP Right Grant
- 2016-08-09 HK HK16109484.6A patent/HK1221473A1/zh not_active IP Right Cessation
-
2017
- 2017-04-11 US US15/485,159 patent/US20170210807A1/en not_active Abandoned
- 2017-08-02 NO NO20171287A patent/NO342491B1/no unknown
- 2017-08-02 NO NO20171288A patent/NO342319B1/no unknown
- 2017-09-29 US US15/721,227 patent/US20180291104A1/en not_active Abandoned
-
2018
- 2018-09-12 HR HRP20181459TT patent/HRP20181459T1/hr unknown
-
2019
- 2019-03-20 US US16/358,874 patent/US20200048354A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012107050A5 (ja) | ||
JP2016063812A5 (ja) | ||
JP2020504101A5 (ja) | ||
ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
JP2018521638A5 (ja) | ||
HRP20192052T1 (hr) | Protutijela anti-siglec-8 te njihovi postupci i uporabe | |
JP2012116856A5 (ja) | ||
RU2018125624A (ru) | Антитела к с5 и способы их применения | |
PE20141562A1 (es) | Anticuerpos anti-htra1 y metodos de uso | |
NZ626520A (en) | Anti-lrp5 antibodies and methods of use | |
RU2017128882A (ru) | Антитела к биотину и способы их применения | |
JP2018085988A5 (ja) | ||
RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
HRP20160034T1 (hr) | Humanizirani antagonisti anti-beta7 i njihove uporabe | |
PE20140995A1 (es) | Agonistas de fgfr1 y sus metodos de uso | |
JP2015533795A5 (ja) | ||
RU2017125758A (ru) | Антитела к с5 и способы их применения | |
PE20181336A1 (es) | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos | |
JP2009519718A5 (ja) | ||
AR076030A1 (es) | Anticuerpos anti-fcrh5 (fc-receptor homologo) e inmunoconjugados y metodos de uso | |
RS53942B1 (en) | Antibodies and Immunoconjugates and Their Use | |
RU2014136103A (ru) | Антагонистические антитела против рецептора IL-7 и способы | |
RU2016127812A (ru) | Способы введения антагонистов интегрина бета7 | |
MX2017005987A (es) | Anticuerpos anti-interleucina(il)-1beta y metodos de uso. |